Off-label use of intravitreal bevacizumab: A global conundrum-Reference-Cited by-同舟云学术

Off-label use of intravitreal bevacizumab: A global conundrum

Published:2024-04-22 Issue:5 Volume:72 Page:617-619
ISSN:0301-4738
Container-title:Indian Journal of Ophthalmology
language:en
Short-container-title:

Author:

Singh Samya¹,Saxena Sandeep¹,Akduman Levent²,Meyer Carsten H³

Affiliation:

1. Department of Ophthalmology, King George’s Medical University, Lucknow, Uttar Pradesh, India

2. Department of Ophthalmology, Eye Institute, St. Louis University, St. Louis, MO, USA

3. Department of Ophthalmology, Eye Center, Grischun, Chur, Switzerland

Abstract

Bevacizumab is a monoclonal, humanized, full-length antibody targeting vascular endothelial growth factor(VEGF-A), known for its anti-angiogenic properties. The off-label use of bevacizumab has stirred legal, financial, industrial, and ethical complexities. With its potential to treat diverse ocular conditions, this commentary delves into the multifaceted dimensions of bevacizumab’s off-label utilization, encompassing clinical trials, regulatory frameworks, safety considerations, comparative effectiveness, and economic implications.

Publisher

Medknow

Reference22 articles.

1. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy;Ferrara;Biochem Biophys Res Commun,2005

2. Optical coherence tomography findings after intravitreal injection of Bevacizumab (Avastin) for neovascular age-related macular degeneration;Rosenfeld;Ophthalmic Surg Lasers Imaging,2005

3. A new colonialism- conducting clinical trials in India;Nundy;N Engl J Med,2005

4. Off label use of medicines: Medical research and medical practice;Khamar;Indian J Ophthalmol,2007

5. Off-label prescribing among office-based physicians;Radley;Arch Intern Med,2006